Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E18.15 EPS (ttm)2.40 Insider Own0.10% Shs Outstand5.88B Perf Week1.19%
Market Cap255.68B Forward P/E14.19 EPS next Y3.07 Insider Trans-12.05% Shs Float5.86B Perf Month0.93%
Income14.41B PEG2.43 EPS next Q0.65 Inst Own73.10% Short Float0.79% Perf Quarter5.73%
Sales53.37B P/S4.79 EPS this Y68.20% Inst Trans0.01% Short Ratio2.16 Perf Half Y21.97%
Book/sh12.14 P/B3.58 EPS next Y2.03% ROA14.20% Target Price43.74 Perf Year23.29%
Cash/sh2.93 P/C14.83 EPS next 5Y7.48% ROE33.70% 52W Range33.20 - 45.81 Perf YTD20.15%
Dividend1.36 P/FCF27.88 EPS past 5Y10.40% ROI11.00% 52W High-5.00% Beta0.85
Dividend %3.12% Quick Ratio1.20 Sales past 5Y-0.80% Gross Margin79.10% 52W Low31.08% ATR1.06
Employees90200 Current Ratio1.40 Sales Q/Q1.00% Oper. Margin26.40% RSI (14)49.47 Volatility2.14% 2.43%
OptionableYes Debt/Eq0.58 EPS Q/Q45.80% Profit Margin44.60% Rel Volume0.87 Prev Close44.11
ShortableYes LT Debt/Eq0.47 EarningsOct 30 BMO Payout33.40% Avg Volume21.53M Price43.52
Recom2.70 SMA20-0.29% SMA50-0.07% SMA20012.60% Volume18,716,463 Change-1.34%
Nov-01-18Downgrade BMO Capital Markets Outperform → Market Perform
Jun-08-18Initiated Cantor Fitzgerald Overweight $45
Apr-05-18Downgrade Barclays Overweight → Equal Weight $41 → $38
Jan-29-18Reiterated SunTrust Hold $33 → $40
Sep-20-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-20-17Downgrade Credit Suisse Outperform → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Nov-13-18 07:00AM  Walmart, Home Depot adopt health insurer tactic in drug copay battle Reuters
Nov-12-18 05:45PM  Pfizer (PFE) Stock Moves -0.38%: What You Should Know Zacks
04:21PM  These Biopharmas Could Cure Genetic Diseases At $5 Million Apiece Investor's Business Daily
Nov-11-18 01:40PM  Hedge Funds Continue to Sell Off Pfizer Inc. (PFE) Insider Monkey
06:37AM  Better Buy: Amgen Inc. vs. Pfizer Inc. Motley Fool
Nov-09-18 07:31AM  Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug Zacks
Nov-08-18 07:32PM  ICU Medical Inc (ICUI) Q3 2018 Earnings Conference Call Transcript Motley Fool
10:43AM  Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up Zacks
04:39AM  AstraZeneca sees years of growth as drug sales turn corner Reuters
Nov-07-18 09:25PM  Nektar Therapeutics (NKTR) Q3 2018 Earnings Conference Call Transcript Motley Fool
04:09PM  These 5 Dow Jones Stocks Just Made This Bullish Move Investor's Business Daily
02:39PM  MARKETS: Oil heading into bear market territory Yahoo Finance Video
12:42PM  Pfizer Rises 3% Investing.com
12:16PM  'We have a lot of things in common' Trump wants to work with Democrats on infrastructure, drugs CNBC
11:30AM  Tariffs, Drug Prices, Legislative Gridlock: What Economists Are Watching Following The Midterm Election Benzinga
11:10AM  NMC Healthcare Sukuk Limited -- Moody's assigns Ba1 rating to NMC's trust certificates Moody's
Nov-06-18 05:45PM  Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know Zacks
04:20PM  MARKETS: Pharma stocks making moves ahead of midterms Yahoo Finance Video
03:15PM  Eli Lilly's Conservative Pricing Offers Protection From Political Pressure TheStreet.com
08:30AM  New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers PR Newswire
Nov-05-18 04:03PM  Bulls & Bears Of The Week: Amazon, Apple, Ford, GE And More Benzinga
02:28PM  Biogen Stock Rebounds After Impressive Q3 Earnings InvestorPlace
10:00AM  Hedge Funds Are Piling Into This Stock Insider Monkey
Nov-02-18 06:34PM  FDA approves Pfizer's treatment for certain lung cancer patients Reuters
05:18PM  Stocks finish lower after a volatile trading session Yahoo Finance Video
04:42PM  U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC Business Wire
11:41AM  Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO Zacks
10:50AM  AbbVie Earnings, Revenue beat in Q3 Investing.com
08:10AM  Report: Exploring Fundamental Drivers Behind Pfizer, eBay, ABM Industries, Quad Graphics, FireEye, and BJ's Restaurants New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
08:09AM  Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus Zacks
06:55AM  Dow 30 Stock Roundup: Apple, Coca-Cola, DowDuPont Earnings Impress Zacks
Nov-01-18 06:31PM  Pfizer and Coca-Cola Earnings Help Safer Income Stocks Shine Zacks
01:28PM  Pfizer cut to market perform at BMO CNBC Videos
12:18PM  BMO: Significant Headwinds Will Cap Pfizer Upside Investopedia
10:54AM  BMO Downgrades Pfizer After Q3 Print, Says Risk-Reward 'Fairly Balanced' Benzinga
10:52AM  Edited Transcript of PFE earnings conference call or presentation 30-Oct-18 2:00pm GMT Thomson Reuters StreetEvents
10:50AM  Has Pfizer (PFE) Outpaced Other Medical Stocks This Year? Zacks
10:08AM  Zoetis Inc Earnings, Revenue beat in Q3 Investing.com
09:55AM  3 Pharma Stocks to Make a Portfolio Feel Better Investopedia
09:43AM  Pfizer weighing sale of women's health portfolio - Bloomberg Reuters
08:46AM  Here's What Exact Sciences Just Said About Its Future Motley Fool
08:21AM  Pfizer downgraded by BMO: 'Significant headwinds' will cap the drugmaker's stock run CNBC
07:45AM  Stocks making the biggest move premarket: DWDP, NFX, ECA, AAPL, CI & more CNBC
07:33AM  Pfizer will go back to price hikes as normal come January, CEO suggests MarketWatch
Oct-31-18 06:28PM  Baxter Earnings beat, Revenue misses In Q3 Investing.com
12:29PM  10 Hot Stocks to Buy Right Now InvestorPlace
12:27PM  Big Pharma's Price Freezes Aren't Fooling Anybody Bloomberg
08:00AM  Todays Research Reports on Stocks to Watch: Daxor and Pfizer ACCESSWIRE
Oct-30-18 08:13PM  [$$] Pfizer Narrows Guidance on Tougher Pricing, Generic Competition The Wall Street Journal
07:06PM  Amgen Earnings, Revenue beat in Q3 Investing.com
06:06PM  Business Highlights Associated Press
04:12PM  Dow Closes Sharply Higher as Late Surge Pushes Stock Gains TheStreet.com
03:28PM  Pfizers Hospital-Drug Problems Wont Go Away Bloomberg
03:00PM  5 Things You Might Miss in Pfizer's Q3 Earnings Without Reading the Fine Print Motley Fool
02:36PM  Profit for Viagra-maker Pfizer spikes in Q3 American City Business Journals
02:12PM  Pfizer revenue worse than expected as generic competition weighs Reuters
02:11PM  Pfizer revenue worse than expected as generic competition weighs Reuters
02:07PM  Pfizer revenue worse than expected as generic competition weighs Reuters
01:41PM  Pharma's support of Trump's drug pricing plan is fraying heading into midterms CNBC
01:25PM  US STOCKS-Wall Street moves higher as chip stocks rebound Reuters
01:13PM  Pfizer's 3Q profit, up due to tax cut, beats expectations Associated Press
12:47PM  [$$] Pfizer Narrows Guidance on Tougher Pricing, Generic Competition The Wall Street Journal
12:26PM  Pfizer CEO says tying drug prices to foreign countries is... CNBC Videos
12:15PM  US STOCKS-Wall Street gains as chip stocks lead bounce back Reuters
12:02PM  Pfizer's Lingering Hospira Woes Are Troubling Bloomberg
11:36AM  HCA Earnings, Revenue beat in Q3 Investing.com
11:31AM  Stocks - Coca-Cola, Apple Gain in Pre-market; GE, Pfizer Sink Investing.com
10:54AM  Pfizer (PFE) Beats on Q3 Earnings, Meets Sales, Narrows View Zacks
10:38AM  Pfizer CEO designate does not see need for large acquisitions Reuters
10:27AM  US STOCKS-U.S. stocks ride higher on trade optimism Reuters
10:02AM  Stocks - U.S. Futures Rise As GE, Coca-Cola Report Earnings Investing.com
09:50AM  Pfizer cuts revenue forecast as supply snags, dollar strength weigh Reuters
09:50AM  Pfizer Earnings beat, Revenue misses In Q3 Investing.com
09:47AM  Pfizer Narrows Forecast as Older Drugs Business Struggles Bloomberg
09:37AM  Stocks struggle to rebound after mixed earnings from Coca-Cola and Pfizer, downbeat housing report MarketWatch
09:06AM  Top 5 Things to Know in the Market on Tuesday Investing.com
08:59AM  US STOCKS-Wall St set to open higher on trade optimism Reuters
08:31AM  Pfizer cuts revenue forecast as supply snags, dollar strength weigh Reuters
08:00AM  Pfizer (PFE) Q3 Earnings Beat Estimates Zacks
08:00AM  Pfizer Tops Q3 Earnings Estimate, Narrows Full-Year Guidance Range TheStreet.com
07:50AM  US STOCKS-Futures higher on Trump's optimistic comments on China trade deal Reuters
07:48AM  Stocks making the biggest move premarket: KO, GE, PFE, TPR, UAA & more CNBC
07:37AM  [$$] Pfizer outlook dented by strong dollar and legacy drug unit Financial Times
07:17AM  Pfizer's a tan minivan these days and that's a good thing... CNBC Videos
07:06AM  Pfizer posts mixed third-quarter results, narrows full-year forecast, shares drop CNBC
06:57AM  Pfizer's stock falls after profit beats, but revenue misses MarketWatch
06:45AM  PFIZER REPORTS THIRD-QUARTER 2018 RESULTS Business Wire
06:40AM  Pfizer posts mixed quarter CNBC Videos
Oct-29-18 07:57PM  Day Ahead: Top 3 Things to Watch Investing.com
03:02PM  Pfizer earnings: Looking toward an ambitious 2022 agenda MarketWatch
02:36PM  7 Bitcoin Stocks That You Wont Lose Your Shirt Over InvestorPlace
02:18PM  Pfizer's Q3 Earnings Preview Benzinga
01:41PM  Stocks Attempt Rally, IBM Buys Red Hat, & Q3 Earnings Season Stays Hot Zacks
11:12AM  What's in Store for Sangamo (SGMO) This Earnings Season? Zacks
02:23AM  Novartis, Pfizer join forces on potentially lucrative fatty liver disease Reuters
02:15AM  Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH Business Wire
Oct-28-18 05:48PM  This Big Pharma Bet Isn't Paying Off Yet -- and It's Costing You Motley Fool
Oct-27-18 07:00AM  Where Will Gilead Sciences, Inc. Be in 5 Years? Motley Fool
Oct-26-18 02:29PM  Dow clawing back earlier losses after S&P dips into correction territory Yahoo Finance Video
01:05PM  BioMarin (BMRN) Q3 Earnings & Revenues Surpass Estimates Zacks
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brands. This segment also engages in the research and development, as well as contract manufacturing activities. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; Immutep Limited; BioNTech AG; Neofluidics, LLC; Kite Pharma, Inc.; Merck KGaA; and Leap Therapeutics, Inc., as well as development agreement with Antares Pharma, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
READ IAN CChairman & CEONov 02Option Exercise26.641,100,20129,312,5881,760,958Nov 06 03:46 PM
PFIZER INC10% OwnerOct 15Buy18.0055,5561,000,00822,032,040Oct 17 05:17 PM
Dolsten MikaelPresident R&DSep 13Option Exercise24.56181,7124,462,167234,299Sep 17 04:08 PM
OLSON LAURIE JExecutive Vice PresidentAug 13Sale41.0010,214418,77472,672Aug 14 05:04 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentAug 03Sale39.5125,6421,013,171102,412Aug 06 03:19 PM
GOETTLER MICHAELGroup PresidentAug 01Sale39.7019,198762,11611,924Aug 03 03:38 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerAug 01Sale40.1626,8141,076,93383,846Aug 03 03:36 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentAug 01Sale40.0420,942838,5724,643Aug 03 03:35 PM
DAMELIO FRANK AExecutive Vice PresidentAug 01Sale40.00150,4846,019,360337,391Aug 03 03:33 PM
SUSMAN SALLYExecutive Vice PresidentJul 20Sale37.2240,3811,502,925115,096Jul 24 01:09 PM
READ IAN CChairman & CEOJul 16Sale37.36486,75318,186,315659,440Jul 17 04:59 PM
OLSON LAURIE JExecutive Vice PresidentJun 06Sale36.4519,000692,58282,886Jun 08 01:11 PM
CORNWELL W DONDirectorJun 04Sale36.405,223190,1170Jun 05 04:44 PM
READ IAN CChairman & CEOMay 01Sale36.01132,3124,764,0811,144,703May 03 04:19 PM
JOHNSON RADY AExecutive Vice PresidentMar 13Sale36.5527,323998,66643,178Mar 14 05:19 PM
LANKLER DOUGLAS MExecutive Vice PresidentMar 13Sale36.8950,0001,844,39883,857Mar 14 05:13 PM
Dolsten MikaelPresident R&DMar 09Sale36.5969,6992,550,39451,185Mar 12 05:01 PM
HILL CHARLES HExecutive Vice PresidentMar 06Sale35.7642,3931,515,98557,328Mar 07 04:09 PM
Dolsten MikaelPresident R&DMar 02Sale35.8513,986501,398120,884Mar 05 09:23 AM
HILL CHARLES HExecutive Vice PresidentFeb 28Option Exercise27.37101,8722,788,237207,942Mar 02 03:24 PM
YOUNG JOHN DGroup PresidentFeb 28Option Exercise27.37121,1453,315,739362,707Mar 02 04:10 PM
OLSON LAURIE JExecutive Vice PresidentFeb 28Option Exercise27.3738,5461,055,004132,702Mar 02 04:02 PM
READ IAN CChairman & CEOFeb 28Option Exercise27.37649,78017,784,4791,774,184Mar 02 04:03 PM
SUSMAN SALLYExecutive Vice PresidentFeb 28Option Exercise27.37110,1323,014,313245,362Mar 02 04:03 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 28Option Exercise27.3719,273527,50239,801Mar 02 03:44 PM
JOHNSON RADY AExecutive Vice PresidentFeb 28Option Exercise27.3719,273527,50285,910Mar 02 03:44 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 28Option Exercise27.3746,8061,281,080171,276Mar 02 03:44 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 28Option Exercise27.37104,6262,863,614384,219Mar 02 03:44 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 28Option Exercise27.37209,2515,727,200655,161Mar 02 03:24 PM
BOURLA ALBERTChief Operating OfficerFeb 28Option Exercise27.3739,9231,092,693184,120Mar 02 03:24 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 28Option Exercise27.3733,040904,305136,847Mar 02 03:24 PM
Dolsten MikaelPresident R&DFeb 28Option Exercise27.37198,2385,425,774293,352Mar 02 03:24 PM
HILL CHARLES HExecutive Vice PresidentFeb 28Sale36.8326,779986,292181,163Mar 02 03:24 PM
SUSMAN SALLYExecutive Vice PresidentFeb 27Sale37.0333,3681,235,591135,230Feb 28 06:14 PM
Dolsten MikaelPresident R&DFeb 27Sale37.0464,5872,392,31395,114Feb 28 06:04 PM
CORNWELL W DONDirectorFeb 27Sale37.0530011,1150Feb 28 01:29 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 26Sale37.199,510353,67717,770Feb 27 07:38 PM
CORNWELL W DONDirectorFeb 26Sale36.741,45853,5640Feb 28 01:29 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9043,520822,528223,733Feb 27 08:59 PM
READ IAN CChairman & CEOFeb 24Option Exercise19.83903,55917,917,2651,560,007Feb 27 08:58 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9015,716297,03290,222Feb 27 07:53 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.9091,8761,736,456206,972Feb 27 07:51 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9015,885300,22762,848Feb 27 07:43 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9028,288534,643112,081Feb 27 07:43 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.9091,8761,736,456313,499Feb 27 07:43 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 24Option Exercise18.9015,957301,58736,959Feb 27 07:38 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentFeb 24Option Exercise18.9039,555747,590143,152Feb 27 07:38 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9065,2801,233,792122,609Feb 27 07:38 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90174,0813,290,131225,265Feb 27 07:32 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9028,288534,643116,769Feb 27 07:30 PM
BOURLA ALBERTChief Operating OfficerFeb 24Option Exercise18.9025,387479,814158,170Feb 27 07:30 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90174,0813,290,131511,470Feb 27 07:30 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentDec 15Sale37.006,750249,750103,458Dec 18 06:17 PM
JOHNSON RADY AExecutive Vice PresidentDec 15Sale37.078,000296,56046,963Dec 18 06:17 PM